424
Views
7
CrossRef citations to date
0
Altmetric
Research Article

Stability of HE4 and CA125 in blood samples from patients diagnosed with ovarian cancer

, , , , &
Pages 477-484 | Received 06 Jun 2013, Accepted 27 Dec 2013, Published online: 13 Apr 2014

References

  • Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10–29.
  • Høgdall CK, Nielsen MLS. Taaning L. Year rapport 2011. Danish Gynecologic Cancer Database. A nationwide clinical database for cancer in ovaries, uterus and cervix. Lægeforeningens forlag, Copenhagen. ISNN: 1903-0223 (online) 2012; Table 14.1.1.
  • Engholm G, Storm HH, Ferlay J, Christensen N, Gjerstorff ML, Johannesen TB, Klint Å, Milter MC, Køtlum JE, Pukkala E, Ólafsdóttir E, NORDCAN: Cancer incidence, mortality, prevalence and survival in the Nordic countries, Version 4.0. Association of the Nordic Cancer Registries. Danish Cancer Society 2011. http://www-dep.iarc.fr/nordcan.htm.
  • Kræftprofil - æggestokkræft 2000–2006. 2009. Sundhedsstyrelsen. http://www.sst.dk/publ/Publ2009/EPT/Kraeftprofiler/Kraeftprofil_Aeggestokkraeft2000-2006.pdf.
  • O’Brien TJ, Beard JB, Underwood LJ, Dennis RA, Santin AD, York L. The CA 125 gene: an extracellular superstructure dominated by repeat sequences. Tumour Biol 2001;22:348–66.
  • Yin BW, Lloyd KO. Molecular cloning of the CA 125 ovarian cancer antigen: identification as a new mucin, MUC16. J Biol Chem 2001;276:27371–5.
  • Bast RC Jr, Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 1981;68:1331–7.
  • Kabawat SE, Bast RC Jr, Bhan AK, Welch WR, Knapp RC, Colvin RB. Tissue distribution of a coelomic-epithelium-related antigen recognized by the monoclonal antibody OC125. Int J Gynecol Pathol 1983;2:275–85.
  • Bast RC Jr, Knapp RC. Use of the CA 125 antigen in diagnosis and monitoring of ovarian carcinoma. Eur J Obstet Gynecol Reprod Biol 1985;19:354–6.
  • Einhorn N, Bast RC Jr, Knapp RC, Tjernberg B, Zurawski VR Jr. Preoperative evaluation of serum CA 125 levels in patients with primary epithelial ovarian cancer. Obstet Gynecol 1986;67:414–6.
  • Høgdall CK, Mogensen O, Tabor A, Mogensen B, Jakobsen AK, Nørgaard-Pedersen B, Larsen SO, Clemmensen I. The role of serum tetranectin, CA 125, and a combined index as tumor markers in women with pelvic tumors. Gynecol Oncol 1995;56:22–8.
  • Santillan A, Garg R, Zahurak ML, Gardner GJ, Giuntoli RL 2nd, Armstrong DK, Bristow RE. Risk of epithelial ovarian cancer recurrence in patients with rising serum CA-125 levels within the normal range. J Clin Oncol 2005;23:9338–43.
  • Duffy MJ, Bonfrer JM, Kulpa J, Rustin GJ, Soletormos G, Torre GC, Tuxen MK, Zwirner M. CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use. Int J Gynecol Cancer 2005;15:679–91.
  • Riedinger JM, Bonnetain F, Basuyau JP, Eche N, Larbre H, Dalifard I, Wafflart J, Ricolleau G, Pichon MF. Change in CA 125 levels after the first cycle of induction chemotherapy is an independent predictor of epithelial ovarian tumour outcome. Ann Oncol 2007;18:881–5.
  • Goonewardene YI, Hall MR, Rustin GJ. Management of asymptomatic patients on follow-up for ovarian cancer with rising CA 125 concentrations.Lancet Oncol 2007; 8:813–21.
  • Bouchard D, Morisset D, Bourbonnais Y, Tremblay GM. Proteins with whey-acidic-protein motifs and cancer. Lancet Oncol 2006;7:167–74.
  • Drapkin R, von Horsten HH, Lin Y, Mok SC, Crum CP, Welch WR, Hecht JL. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res 2005;65: 2162–9.
  • Hellström I, Raycraft J, Hayden-Ledbetter M, Ledbetter JA, Schummer M, McIntosh M, Drescher C, Urban N, Hellström KE. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res 2003;63:3695–700.
  • Moore RG, Brown AK, Miller MC, Skates S, Allard WJ, Verch T, Steinhoff M, Messerlian G, DiSilvestro P, Granai CO, Bast RC Jr. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol 2008;108:402–8.
  • Moore RG, McMeekin DS, Brown AK, DiSilvestro P, Miller MC, Allard WJ, Gajewski W, Kurman R, Bast RC Jr, Skates SJ. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol 2009; 112:40–6.
  • Karlsen MA, Sandhu N, Høgdall C, Christensen IJ, Nedergaard L, Lundvall L, Engelholm SA, Pedersen AT, Hartwell D, Lydolph M, Laursen IA, Høgdall EV. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass. Gynecol Oncol 2012;127:379–83.
  • Gao YC, Yuan ZB, Yang YD, Lu HK. Effect of freeze- thaw cycles on serum measurements of AFP, CEA, CA125 and CA19-9. Scand J Clin Lab Invest 2007;67:741–7.
  • Sparholt MH, Høgdall CK, Nedergaard L, Heeran MC, Christensen IJ, Høgdall EV. Is tissue CA125 expression in epithelial ovarian adenocarcinoma heterogenic?APMIS 2013;121:38–44.
  • Banfi G, Parma P, Pontillo M. Stability of tumor markers CA 19.9, CA 125, and CA 15.3 in serum obtained from plain tubes and tubes containing thixotropic gel separator. Clin Chem 1997;43:2430–1.
  • Høgdall EV, Johansen JS, Kjaer SK, Price PA, Blaakjaer J, Høgdall CK. Stability of YKL-40 concentration in blood samples. Scand J Clin Lab Invest 2000;60:247–51.
  • Hogdall EV, Hogdall CK, Kjaer SK, Xu F, Yu Y, Bast RC, Blaakaer J, Jacobs IJ. OVX1 radioimmunoassay results are dependent on the method of sample collection and storage. Clin Chem 1999;45:692–4.
  • Begum FD, Høgdall E, Christensen IJ, Kjaer SK, Blaakaer J, Christensen L, Høgdall C. Serum tetranectin is a significant prognostic marker in ovarian cancer patients. Acta Obstet Gynecol Scand 2010;89:190–8.
  • Høgdall CK, Høgdall EV, Hørding U, Clemmensen I, Nørgaard-Pedersen B, Toftager-Larsen K. Pre-operative plasma tetranectin as a prognostic marker in ovarian cancer patients. Scand J Clin Lab Invest 1993;53:741–6.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.